augmenix boston scientific

All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. Trish.backes@bsci.com, Susie Lisa, CFA Tesla Inc. Chief Executive Elon Musk promises a price cut on the Model S luxury sedan. Privacy Notice and "The injection of this hydrogel during a minimally-invasive, in-office procedure can reduce the unwanted and unintended side effects of prostate radiation and provide substantial peace of mind for patients and their treating physicians.". The transaction is expected to be immaterial to Boston Scientific’s adjusted earnings through next year and then become profitable on an adjusted basis thereafter. Boston Scientific Corporation This cautionary statement is applicable to all forward-looking statements contained in this document. The transaction is expected to be immaterial to adjusted earnings per share in 2018 and 2019, accretive in 2020 and increasingly accretive thereafter. The deal also provides for … October 17, 2018 By Brad Perriello Boston Scientific (NYSE: BSX) said yesterday that it closed the $600 million acquisition of Augmenix and its SpaceOar device. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes. Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. "We are proud of the clinical and commercial outcomes we've been able to achieve for SpaceOAR hydrogel thus far, and are excited to drive accelerated adoption leveraging Boston Scientific's urology and pelvic health expertise," said John Pedersen, chief executive officer, Augmenix. A single injection of the SpaceOAR hydrogel is designed to maintain the space between the rectum and prostate for three months – within the duration of a standard radiation treatment schedule. Top. Additionally, the randomized SpaceOAR hydrogel U.S. clinical trial demonstrated that patients who received the hydrogel spacer reported significantly less rectal pain during prostate radiotherapy and had significantly less severe long-term rectal complications, including zero incidence of grade 2 rectal toxicity versus a 5.7% rate experienced by patients without the spacer. "The injection of this hydrogel during a minimally-invasive, in-office procedure can reduce the unwanted and unintended side effects of prostate radiation and provide substantial peace of mind for patients and their treating physicians.". Boston Scientific Closes Acquisition of Augmenix, Inc. Cardiac Resynchronization Therapy (CRT) Devices, Medical Device ID Cards - Pacemaker, ICD, & CRT devices, Remote Patient Monitoring and Diagnostic Monitoring - Boston Scientific. BSXInvestorRelations@bsci.com. Boston Scientific Corp. has agreed to buy Augmenix Inc., which developed the SpaceOAR hydrogel product that helps reduce side effects from prostate cancer radiotherapy. Hong Kong and Singapore say they have agreed to a bilateral air travel bubble, re-establishing travel links as coronavirus infections in both cities decline. The acquisition is projected to close early in the fourth quarter of 2018, subject to customary closing conditions. Additional information about Augmenix and the SpaceOAR Hydrogel can be found at www.spaceoar.com. About Boston Scientific This cautionary statement is applicable to all forward-looking statements contained in this document. I give Boston Scientific permission to contact me via email or by the phone number I have provided. To order presentation-ready copies for distribution to your colleagues, clients or customers visit https://www.djreprints.com. These forward-looking statements include, among other things, statements regarding our business plans, regulatory approvals, product development and product performance and impact. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook. Boston Scientific. Massachusetts-based Augmenix will receive $500 million in upfront cash and another $100 million in future milestone payments through the deal. By using this site you agree to the I acknowledge that I am a U.S. resident. The company's hydrogel is clinically proven to minimize side effects and protect quality of life for prostate cancer patients undergoing radiation therapy, enabling healthcare providers to minimize urinary, sexual and bowel side effects of the patients. Cancer Base No. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook. A news release about the deal said clinical trials for gel therapy found that it significantly reduced the amount of radiation delivered to the rectum, and the associated pain. Clinical trials in Europe and the U.S. have demonstrated that the space created by the hydrogel significantly reduces the amount of radiation delivered to the rectum. Augmenix General Information Description. We will get in touch with you shortly . President Donald Trump and challenger Joe Biden will compete for TV audiences in dueling town hall meetings instead of meeting face-to-face for their second debate as originally planned. The biodegradable SpaceOAR hydrogel is injected between the rectum and prostate to decrease a patient's exposure to rectal radiation and thereby reduce rectal radiation injury – one of the most common complications of prostate radiotherapy. Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. As a result of commercial adoption, expanded U.S. reimbursement and a total addressable market valued at $750M, product sales are estimated to reach $50M in 2018, and approach $90M in 2019. Technology Investor Lead Edge Capital Raises $950 Million as VC Sector Swells, Insight Partners Seeks $875 Million for Debut Preferred-Equity Strategy, Venture Capital Struggles to Boost Funding for Startups With Women Founders, New Heritage Capital Banks Roughly $270 Million for Latest Fund. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. All trademarks are the property of their respective owners. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. Shares of Boston Scientific rose 0.2% in the extended session after ending the regular trading day up 0.7%. 2 Data on file. Clinical trials in Europe and the U.S. have demonstrated that the space created by the hydrogel significantly reduces the amount of radiation delivered to the rectum. For further information regarding our non-GAAP measures, see Part II, Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K, which we may update in Quarterly Reports on Form 10-Q we have filed or will file hereafter. (508) 683-5565 (office) Investor Relations Boston Scientific has been ramping up investments in men’s health in recent years, including more $2 billion worth of acquisitions for Maple Grove’s NxThera and the prostate division of the former American Medical Systems in Minnetonka since 2015. These forward-looking statements include, among other things, statements regarding our business plans, regulatory approvals, the closing of the acquisition, product development and product performance and impact. Use of Non-GAAP Financial Measures Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. Explore Educare, our globally recognized education program, Fueling the next generation of life science professionals. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. MARLBOROUGH, Mass., Sept. 6, 2018 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the SpaceOAR® System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. All rights reserved. Posted in Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Prostate cancer is often treated with radiation, but the therapy can create pain and lingering rectal problems because the rectum is physically so close to the prostate. Boston Scientific (NYSE: BSX) is to acquire Augmenix, Inc., a Bedford, MA-based company which has developed and commercialized the SpaceOAR® System, a therapy used to … This includes occasional communications about our product(s). Each year, more than 1.1 million men are diagnosed with prostate cancer worldwide and approximately 400,000 men will undergo prostate radiotherapy.1,2 One of the most common complications of treatment is rectal radiation injury, due to the rectum's proximity to the prostate and the resulting high doses of inadvertent radiation exposure.

Bavaria History, Jeff Healey I Should Have Told You, South Korean Navy Uniform, Quake Iii Arena Platforms, BANG BANG BANG, The Diameter Of The Millennium Dome, Monash University Ranking In Australia, Dark Night Of The Soul,

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *